TY - JOUR
T1 - Identifying Drug Repurposing Opportunities in Oncology
AU - Orecchioni, Stefania
AU - Roma, Stefania
AU - Raimondi, Sara
AU - Gandini, Sara
AU - Bertolini, Francesco
PY - 2019/3/1
Y1 - 2019/3/1
N2 - The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field.
AB - The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field.
KW - Anticancer drugs
KW - drug repurposing
KW - oncology drugs
UR - http://www.scopus.com/inward/record.url?scp=85063648480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063648480&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000360
DO - 10.1097/PPO.0000000000000360
M3 - Review article
C2 - 30896529
AN - SCOPUS:85063648480
VL - 25
SP - 82
EP - 87
JO - Cancer Journal from Scientific American
JF - Cancer Journal from Scientific American
SN - 1528-9117
IS - 2
ER -